Kalorama Forecasts $2.3 Billion Hba1c Market By 2029, Driven By POC Growth, Emerging Markets, And Digital Innovation

(MENAFN- PR Newswire) In 2024, the global HbA1c in vitro diagnostics (IVD) market generated $1.7 billion and is projected to reach $2.3 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.7%. The report underscores the growing role of HbA1c testing in diabetes screening, monitoring, and personalized care-particularly as point-of-care (POC) adoption accelerates to meet demand for fast, decentralized diagnostics.

"Laboratory-based testing has long been the gold standard for HbA1c," said Daniel Granderson, Senior Editor at Kalorama Information. "But with advancing technology and rising demand, we're seeing a significant shift toward POC testing. These platforms have been a major driver of diagnostics market growth over the past decade."

Key Findings:

• North America and Europe accounted for over 73% of 2024 revenues, but Asia-Pacific and Latin America are gaining momentum due to aging populations, rising diabetes prevalence, and expanding healthcare systems.
  
• Lab-based HbA1c testing remains dominant, but POC platforms are growing faster due to convenience and innovation.
  
• Abbott leads the market with a 17% share, followed by Roche (11%) and Bio-Rad. The top five HbA1c competitors combine to account for 45% of the overall market.
  
• Emerging technologies-nanotech, mobile-connected assays, AI, and deep learning-are enabling real-time, home-based monitoring and predictive care.

Why This Report Matters Now:

As global diabetes rates climb and healthcare systems emphasize chronic disease management and cost control, HbA1c testing is central to improving outcomes. The integration of digital tools, biosensor innovation, and government screening programs is reshaping how and where testing is done. This report gives stakeholders a clear view of:

• Where growth is happening (geographically and technologically)
  
• How to enter or expand in the market
  
• Which products and competitors are gaining share
  
• What barriers exist in reimbursement, pricing, and procurement
  
• How to prioritize investments and R&D pipelines

Who Should Read This Report:

• Diagnostic & Medical Device Companies
  
• Strategic Planners & Business Development Leaders
  
• Investors and Venture Capital Firms
  
• Healthcare Providers and Laboratory Networks
  
• Policy Makers and Reimbursement Authorities

Whether you're building a product roadmap, evaluating acquisition targets, or justifying a strategic pivot, this report provides the data, competitive intelligence, and trend forecasting you need to move forward with confidence.

Access the Report & Webinar

• Purchase the Report
• Watch the Webinar Replay

For more information or to request a custom consultation, contact:
Sheri Davie
Kalorama Information Sales Team
[email protected]

For all other inquiries contact:
Alisa Alvich
Marketing Director
[email protected]

About Kalorama Information

For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike.

SOURCE Kalorama Information

MENAFN04062025003732001241ID1109636873